2OHOA inhibits Notch signaling by downregulating the transcription of Notch pathway components (JAGGED1, NOTCH1, NOTCH3) and preventing the processing of immature Notch2 receptor in both cell lines, triggering a blockage of Notch signaling and, thus, repressing the expression of the Notch target genes HES1 and CD3. Moreover, it should be noted that CD3 was previously described as a target of 2OHOA due to inhibition of the Ras/MAPK pathway [24], suggesting that this bioactive lipid can downregulate different pathways related to glioma proliferation as part of its anti-tumoral effect. The gene discussed is HES1; the disease is central nervous system cancer.